A5026081538- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Animal Virus Infections Studies
- Immunotherapy and Immune Responses
- Vaccine Coverage and Hesitancy
- COVID-19 epidemiological studies
- Heparin-Induced Thrombocytopenia and Thrombosis
- Viral gastroenteritis research and epidemiology
- Bacillus and Francisella bacterial research
- SARS-CoV-2 detection and testing
- Respiratory viral infections research
- Bacterial Infections and Vaccines
- Virus-based gene therapy research
- Influenza Virus Research Studies
- Long-Term Effects of COVID-19
- Viral Infections and Immunology Research
- CAR-T cell therapy research
- COVID-19 Pandemic Impacts
- Streptococcal Infections and Treatments
- Diphtheria, Corynebacterium, and Tetanus
Chulalongkorn University
2020-2024
King Chulalongkorn Memorial Hospital
2020-2024
Thai Red Cross Society
2020-2024
The coronavirus disease 2019 (COVID-19) pandemic has become a severe healthcare problem worldwide since the first outbreak in late December 2019. Currently, COVID-19 vaccine been used many countries, but it is still unable to control spread of acute respiratory syndrome 2 (SARS-CoV-2) infection, despite patients receiving full vaccination doses. Therefore, we aimed appraise booster effect different platforms vaccines, including inactivated (BBIBP), viral vector (AZD122), and mRNA (BNT162b2),...
In light of intermittent supply shortages individual vaccines and evidence rare but serious adverse events after vaccination, heterologous regimens for COVID-19 have gained significant interest. This study aims to assess the reactogenicity immunogenicity adenoviral vector (ChAdOx1-S, AstraZeneca; hereafter referred as AZ) inactivated vaccine regimen (CoronaVac; CV) in healthy Thai adults immunized between June September 2021. Our showed that following homologous CV-CV AZ-AZ, CV-AZ AZ-CV...
The use of an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (CoronaVac) against SARS-CoV-2 is implemented worldwide. However, waning immunity and breakthrough infections have been observed. Therefore, we hypothesized that the heterologous booster might improve protection delta omicron variants.A total 224 individuals who completed 2-dose CoronaVac for 6 months were included. We studied reactogenicity immunogenicity after a with (BBIBP), viral vector...
The coronavirus 2019 omicron variant has surged rapidly and raises concerns about immune evasion even in individuals with complete vaccination, because it harbors mutations. Here we examine the capability of booster vaccination following CoronaVac/AZD1222 prime to induce neutralizing antibodies (NAbs) against (BA.1 BA.2) T-cell responses. A total 167 participants primed heterologous for 4-5 months were enrolled, receive AZD1222, BNT162b2, or mRNA-1273 as a third dose. Reactogenicity was...
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and the waning immunity in vaccinated individuals is resulting increased numbers SARS-CoV-2 breakthrough infections. This study investigated binding antibody responses neutralizing activities against variants, patients with COVID-19 who had been fully CoronaVac (
Abstract Seroprevalence studies on SARS-CoV-2 are essential for estimating actual prevalence rates of infection and vaccination in communities. This study evaluated based total anti-nucleocapsid immunoglobulin (N) and/or history. We determined the seroprevalence anti-receptor binding domain (RBD) antibodies across age groups. A cross-sectional was conducted Chonburi province, Thailand, between October 2022 January 2023. Participants included newborns to adults aged up 80 years. All serum...
Coronavirus disease 2019 (COVID-19) booster vaccination is being comprehensively evaluated globally due to waning immunity and the emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. Therefore, this study aimed evaluate antibody responses in individuals vaccinated with two doses BBIBP-CorV vaccine explore boosting effect different platforms BBIBP-CorV-primed healthy adults, including a viral vector (AZD122) mRNA vaccines (BNT162b2 mRNA-1273). The results...
Background Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection can be asymptomatic in young children. Therefore, the true rate of is likely underestimated. Few data are available on infections children, and studies SARS-CoV-2 seroprevalence among children during omicron wave limited. We assessed infection-induced estimated associated risk factors for seropositivity. Methods A longitudinal serological survey was conducted from January 2021 through December 2022. The...
The SARS-CoV-2 Omicron variant presents numerous mutations potentially able to evade neutralizing antibodies (NAbs) elicited by COVID-19 vaccines. Therefore, this study aimed provide evidence on a heterologous booster strategy overcome the waning immunity against variants.
This study examined the neutralizing activity and receptor-binding domain (RBD) antibody levels against wild-type omicron BA.1 BA.2 variants in individuals who received three doses of COVID-19 vaccination. The relationship between anti-RBD IgG live virus titers was examined. In total, 310 sera samples from after booster vaccination (third-dose) were tested for specific SARS-CoV-2 RBD surrogate neutralization test (sVNT). assay performed using foci-reduction (FRNT50). strongly correlated with...
The Coronavirus disease 2019 (COVID-19) pandemic, caused by Severe Acute Respiratory Syndrome 2 (SARS-CoV-2), continues to surge despite the widespread use of vaccination. In Thailand, more than 77% and 39% population received two doses three COVID-19 vaccines as December 2022, respectively. addition, during Omicron predominant period in 70% Thai individuals have been infected. To gain comprehensive insight into SARS-CoV-2 antibody dynamics following vaccination or infection (hybrid...
Numerous studies have largely focused on short-term immunogenicity in recovered individuals post mRNA vaccination. However, understanding the long-term durability, particularly inactivated and adenoviral vectored vaccines, remains limited. We evaluated antibody responses, omicron variant neutralization, IFN-γ responses 119 previously infected vaccinated with CoronaVac or ChAdOx1 up to six months post-vaccination. Both vaccines elicited robust immune individuals, surpassing those who were...
To report the safety and immunogenicity profile of a protein subunit vaccine (Covovax
Abstract Background The use of an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (CoronaVac) against SARS-CoV-2 is implemented worldwide. However, waning immunity and breakthrough infections have been observed. Therefore, we hypothesized that the heterologous booster might improve protection delta omicron variants. Methods A total 224 individuals who completed two-dose CoronaVac for six months were included. We studied reactogenicity immunogenicity following...
Abstract Coronavirus disease 2019 (COVID-19) booster vaccination is being comprehensively evaluated globally due to waning immunity and the emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. Therefore, this study aimed evaluate antibody responses in individuals vaccinated with two doses BBIBP-CorV vaccine explore boosting effect different platforms BBIBP-CorV-primed healthy adults, including viral vector (AZD122) mRNA vaccines (BNT162b2 mRNA-1273). The...
The aim of this study is to investigate the reactogenicity and immunogenicity fourth dose using monovalent mRNA vaccines after different three-dose regimens compare 30 µg BNT162b2 50 mRNA-1273 vaccines. This prospective cohort was conducted between June October 2022. self-recorded evaluated on subsequent 7 days a dose. binding neutralizing activity antibodies against Omicron BA.4/5 variants were determined. Overall, 292 healthy adults enrolled received or mRNA-1273. Reactogenicity mild...
To assess the binding antibody response and strength of neutralization against Omicron BA.5 in serum samples from children with different antigen exposures (infection/vaccination) hybrid immunity.This study recruited aged 5-7 years. All were tested for anti-nucleocapsid immunoglobulin (Ig)G, anti-receptor domain (RBD) IgG, total anti-RBD Ig. Neutralizing antibodies (nAbs) determined using a focus reduction test.A 196 unvaccinated infection (n = 57), vaccination alone 71), immunity 68). Our...
Abstract This study examined the neutralizing activity and receptor binding domain (RBD) antibody levels against wild-type omicron BA.1 BA.2 variants in individuals who received three doses of COVID-19 vaccination. The relationship between SARS-CoV-2 RBD live virus titers was examined. In total, 310 sera samples from after booster vaccination (third dose) were tested for specific IgG surrogate neutralization test (sVNT). assay performed using foci-reduction (FRNT50). anti-RBD strongly...
Abstract The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and the waning immunity in vaccinated individuals is resulting increased numbers SARS-CoV-2 breakthrough infections. This study investigated binding antibody responses neutralizing activities against patients with COVID-19 who had been fully CoronaVac ( n = 78), but not contracted 170), received AZD1222 as a third vaccination 210). Breakthrough infection was generally detected approximately 88...
Click to increase image sizeClick decrease size AcknowledgmentsWe would like thank the staff of Center Excellence in Clinical Virology and all participants for helping supporting this project. We also Ministry Public Health, Chulabhorn Royal Academy, Zuellig Pharma providing vaccines study.Disclosure statementAll authors have declared no competing interests.Additional informationFundingThis work was supported by National Research Council Thailand, Health Systems Institute, Chulalongkorn...
Abstract In light of intermittent supply shortages individual vaccines and evidence rare but serious adverse events after vaccination, heterologous regimens for COVID-19 have gained significant interest. This study aims to assess the reactogenicity immunogenicity adenoviral vector vaccine regimen (ChAdOx1-S, AstraZeneca; hereafter referred as AZ) inactivated (CoronaVac; CV) in healthy Thai adults immunized between June September 2021. Our showed that following homologous CV-CV AZ-AZ, CV-AZ...